A Phase 1/2 interventional study of INT230-6 and anti-PD-1 antibody in Breast Cancer, Head and Neck Cancer and Squamous Cell Carcinoma, sponsored by Intensity Therapeutics, Inc.. Completed at 8 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-02-27.
Sponsored by Intensity Therapeutics, Inc. · Phase 1/2, Interventional, and Treatment
How we know · 21 judgments
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This study evaluated the intratumoral administration of escalating doses of a novel, experimental drug, INT230-6. The study was conducted in patients with several types of refractory cancers including those at the surface of the skin (breast, squamous cell, head and neck) and tumors within the body such (pancreatic, colon, liver, lung, etc.). Sponsor also tested INT230-6 in combination with anti-PD-1 and anti-CTLA-4 antibodies.
INT230-6 is comprised of 3 agents in a fixed ratio - a cell permeation enhancer and two, potent anti-cancer payloads (cisplatin and vinblastine sulfate). The penetration enhancer facilitates dispersion of the two drugs throughout injected tumors and enables increased diffusion into cancer cells. Nonclinical safety studies showed no findings following drug injection into healthy tissues.
Historically physicians administer the two active drugs comprising INT230-6 by intravenous (IV) infusion to achieve a systemic blood level at the limit of tolerability. The objective is destroy both visible tumors and unseen circulating cancer cells (micro-metastases). Unfortunately, dosing drugs IV delivers only a small amount with a low concentration at the tumor site. This approach especially for late stage cancers is not highly effective and often quite toxic to the patient.
Attempts at direct intratumoral injection with chemotherapeutic agents have not shown the ability to treat the injected tumor, non-injected tumors or micro-metastases. This lack of efficacy for local administration is due possibly to poor dispersion and a lack of cell uptake of the agents.
Due to the use of the novel cell penetration enhancing agent INT230-6 treatment demonstrated strong efficacy in animals having large tumors. The Sponsor's in vivo, non-clinical data shows that INT230-6 thoroughly saturates and kills injected tumors. In addition, the drug induces an adaptive (T-cell mediated) immune response that attacks not only the injected tumor, but non-injected tumors and unseen micro-metastases. Cured animals become permanently immunized against the type of cancer that INT230-6 eliminates.
Clinical trial IT-01 sought to determine the safety and potential efficacy of dosing INT230-6 directly into several different types of cancers. In addition, animal studies showed a strong synergy of INT230-6 with immune modulation agents. Thus, as part of study IT-01 the Sponsor seeks to understand the safety and efficacy of INT230-6 when administered in combination with immuno-therapeutic agents such as antibodies that target Programmed Cell Death (PD-1 or anti-PD-1) and Cytotoxic T-Lymphocyte Associated Protein 4 (CTLA-4 or anti-CTLA-4) receptors.
This study sought to understand whether tumor regression can be achieved, and patient outcomes improved.
14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.
This study's enrollment of 111 is above the median of 72 across 10,921 interventional studies indexed under Breast Neoplasms.
Browse Breast Neoplasms studies →Intensity Therapeutics, Inc. is the lead sponsor of 2 studies on the registry; 1 is open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
INT230-6 monotherapy Cohorts EC2 and EC3, combination with KEYTRUDA® cohort DEC2 and combination with Yervoy cohort FEC. Where criteria diverge the DEC2 and FEC specific criteria will be noted.
Subjects with metastatic disease who have failed one or more approved standard therapies, or have no alternate approved therapy available. Failure of all approved therapies that have a modest or marginal impact on survival is not required as long as the treating physician believes that treatment on study is appropriate for the subject and documents that the subject elects to defer the approved therapies.
Note: There is no limit on the number of prior therapies that a patient (subject) may have received prior to enrollment in any cohort.
Prior chemotherapy or immunotherapy (tumor vaccine, cytokine, or growth factor given to control the cancer: systemic or IT) must have been completed at least 4 weeks prior to dosing (with the exception of kinase inhibitors or other short half-life drugs, a 2 week washout is acceptable prior to treatment) and all adverse events have either returned to baseline or stabilized.
Note: Subjects who have received prior platinum therapy are eligible irrespective of their response.
A female participant is eligible to participate if she is not pregnant, not breastfeeding, and at least one of the following conditions applies:
Have adequate organ function as defined by the below screening laboratory values that must meet the following criteria:
For subjects with planned deep tumor injections: PT, PTT/aPPT, and INR within normal limits; Platelet count ≥100,000/μL; hemoglobin ≥ 9 g/dL.
Note: ALT (SGPT) =alanine aminotransferase (serum glutamic pyruvic transaminase); AST (SGOT) =aspartate aminotransferase (serum glutamic oxaloacetic transaminase); ULN=upper limit of normal.
1 Criteria must be met without erythropoietin dependency and without packed red blood cell (pRBC) transfusion within last 2 weeks.
Additional criteria for combination arms can be found in the appropriate combination protocol supplements. Refer to the Investigative site for details.
Additional Inclusion Criteria for DEC2 cohort (anti-PD1 combination, KEYTRUDA® (pembrolizumab)) Population: Subjects with histologically or cytologically confirmed advanced or metastatic Pancreatic, Cholangiocarcinoma, non-MSI-H and/or MMR proficient colorectal cancer, and Squamous Cell Carcinoma tumors.
Additional Inclusion Criteria for FEC cohort ( combination, Yervoy (ipilimumab)) Population: Subjects with histologically or cytologically confirmed advanced or metastatic Hepatocellular carcinoma (HCC), breast cancer regardless of histology (BC) or soft tissue sarcoma
NOTE: DEC and FEC combination cohorts have additional Inclusion Criteria - refer to the Investigative site for details.
Exclusion Criteria:
For INT230-6 Monotherapy cohort EC3, cohort DEC2-KEYTRUDA® combination and cohort FEC-Yervoy combination
Subjects who exhibit any of the following conditions at screening will not be eligible for admission into the study:
Pregnancy Exclusion:
A who has a positive urine pregnancy test (e.g., within 72 hours) prior to treatment. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required
NOTE: DEC or FEC combination cohorts have additional Exclusion criteria. Refer to the Investigative site for details.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Versions of RECIST adapted to particular cases. iRECIST is for immunotherapy, where a tumor can look bigger for a while before it shrinks, so growth has to be confirmed on a later scan. mRECIST usually means the version for liver cancer (hepatocellular carcinoma), which measures only the part of a tumor that still has a blood supply.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
iRECIST and mRECIST
Versions of RECIST adapted to particular cases. iRECIST is for immunotherapy, where a tumor can look bigger for a while before it shrinks, so growth has to be confirmed on a later scan. mRECIST usually means the version for liver cancer (hepatocellular carcinoma), which measures only the part of a tumor that still has a blood supply.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
INR, PT and aPTT (clotting tests)
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
PD-1, PD-L1 and checkpoint inhibitors
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Dosing: \>=40% Total Tumor Burden A1:INT230-6 injections into only superficial tumors, low starting dose, low concentration per tumor. B1:INT230-6 injections into deep tumors, low starting dose, low drug concentration per tumor Dosing schedule for A1 and B1 is every 28 days for 5 sessions EA:INT230-6 injections into superficial tumors, medium starting dose, low drug concentration per tumor EC:INT230-6 injections into superficial or deep tumors, moderately high starting dose, high drug concentration per tumor EC2:INT230-6 injections into superficial or deep tumors, high starting dose, moderate drug concentration per tumor, higher number of tumors to be treated per session than EC. EC3:INT230-6 injections at fixed maximal dose into superficial or deep tumors, unlimited number of tumors to be treated per session with retreatment once every 9 weeks for two years. Dosing schedule for EA, EC, EC2 and EC3 is every 2 weeks for 5 sessions Completed Cohorts
Drug: INT230-6
Dosing: \<40% Total Tumor Burden A1:INT230-6 injections into only superficial tumors, low starting dose, low concentration per tumor. B1:INT230-6 injections into deep tumors, low starting dose, low drug concentration per tumor Dosing schedule for A1 and B1 is every 28 days for 5 sessions EA:INT230-6 injections into superficial tumors, medium starting dose, low drug concentration per tumor EC:INT230-6 injections into superficial or deep tumors, moderately high starting dose, high drug concentration per tumor EC2:INT230-6 injections into superficial or deep tumors, high starting dose, moderate drug concentration per tumor, higher number of tumors to be treated per session than EC. EC3:INT230-6 injections at fixed maximal dose into superficial or deep tumors, unlimited number of tumors to be treated per session with retreatment once every 9 weeks for two years. Dosing schedule for EA, EC, EC2 and EC3 is every 2 weeks for 5 sessions Completed Cohorts
Drug: INT230-6
DEC: INT230-6 injections every 2 weeks for 5 sessions with the possibility for INT230-6 retreatment into superficial tumors, with addition of anti-PD-1 antibody KEYTRUDA® (pembrolizumab) dosed concurrently starting at Day 1 every 3 weeks for two years for selected cancer types. Completed Cohort DEC2:INT230-6 per the dosing of cohort EC3 combined with KEYTRUDA® (pembrolizumab) dosed per DEC concurrently starting at Day 1 for selected cancers. Completed Cohort
Drug: INT230-6 · Biological: anti-PD-1 antibody
FEC: INT230-6 per the EC3 regimen combined with Yervoy (ipilimumab) dosed concurrently starting at Day 1 every 3 weeks for four treatments for selected cancer types. Completed Cohort anti-CTLA-4 antibody: The anti-CTLA-4 antibody will be added concomitantly with INT230-6 as noted in cohort FEC.
Drug: INT230-6 · Biological: anti-CTLA-4 antibody
INT230-6 is clear sterile solution administered by injection directly into the tumor to be treated. The product contains a cell permeation agent with cisplatin and vinblastine sulfate at fixed concentrations.
The anti-PD-1 antibody will be added concomitantly with INT230-6 as noted in cohort DEC and DEC2
Also known as: pembrolizumab, KEYTRUDA®, MK-3475
The anti-CTLA-4 antibody will be added concomitantly with INT230-6 as noted in cohort FEC
Also known as: ipilimumab, Yervoy, BMS-734016
This study also gives PembrolizumabStudies of PembrolizumabPembrolizumab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.. No intervention listed here names it: that was found by reading the record.
Rate and Severity of Treatment-emergent Adverse Events ≥ Grade 3 Attributed to Study Drug Using the NCI Common Terminology Criteria for Adverse Events (CTCAE v.4.03) (Scale 1 to 5)
The primary objective is to assess the safety and tolerability of single and multiple intratumoral doses of INT230-6 in subjects with advanced or recurrent malignancies. This will be assessed by the rate of ≥ grade 3 AE's attributed to INT230-6 and not the underlying disease. NCI Common Terminology Criteria for Adverse Events (CTCAE v.4.03) (Scale 1 (least severe) to 5 (most severe)) All recorded adverse events will be listed and tabulated by system organ class, preferred term, and dose and coded according to the most current version of MedDRA. The incidence of adverse events will be tabulated and reviewed for potential significance and clinical importance. Adverse Events will be summarized for all reported data and by study period: a) up to and including 28 days post last dose of initial treatment, and b) from first dose of re-initiation of treatment, for subjects who re-initiate study therapy while in follow-up, up to 28 days post-dose of the last re-treatment dose.
Time frame: Up to 5 years
Preliminary Efficacy: Assess the Preliminary Efficacy of INT230-6 by Measuring the Disease Control Rate (DCR) Based on the Response Evaluation Criteria in Solid Tumors (RECIST) and Immune RECIST (iRECIST) Criteria,
Assess the preliminary efficacy of INT230-6 by measuring the disease control rate (CR+PR+SD) as assessed by iRECIST. Complete response (CR) and partial response (PR) will be defined for injected tumors followed per RECIST 1.1 utilizing target lesions. Progressive disease will be determined by clinical or radiological deterioration leading to the subject being taken off-treatment at the discretion of the investigator. Stable disease (SD) is defined as any adequate assessment not considered CR, PR, or progression.
Time frame: Up to 5 years
Determine Pharmacokinetic Parameter Peak Plasma (Cmax in ng/mL) of Each of the 3 Main Components of INT230-6.
Characterize the peak plasma profile for the three INT230-6 components after single and then multiple IT tumor site injections for safety purposes. Timepoints for sample collection were T = 1 Hours after dosing. Mean dose volume categories that were used to summarize data were as follows: 2 mL (range 0 to 3.5 mL) 5 mL (range 3.6 to 6 mL) 10 mL (range \>6 to 12 mL) 17 mL (range \>12 to 24 mL) 30 mL (range \>24 mL to 44 mL) 68 mL (range \>44 to 98 mL) 118 mL (range \>98 to 175 mL)
Time frame: T = 1 hour after first dose
Determine Key Pharmacokinetic Parameter, Area Under the Curve (AUC) (ng/mL) of Each of the 3 Main Components of INT230-6.
Characterize the pharmacokinetic AUC profile of each of the three INT230-6 components for AUC after single IT tumor site injection for safety purposes. Timepoints for sample collection were T = 0, 1, 3, 6, 24 Hours after dosing. Mean dose volume categories that were used to summarize data were as follows: 2 mL (range 0 to 3.5 mL) 5 mL (range 3.6 to 6 mL) 10 mL (range \>6 to 12 mL) 17 mL (range \>12 to 24 mL) 30 mL (range \>24 mL to 44 mL) 68 mL (range \>44 to 98 mL) 118 mL (range \>98 to 175 mL)
Time frame: T= 0, 1, 3, 6, 24 Hours after dosing
Key Pharmacokinetic Parameters, Half Live (Hours) of Each of the 3 Main Components of INT230-6.
Characterize the half life of each of the three INT230-6 components after single and multiple IT tumor site injections for safety purposes. Timepoints for sample collection were T = 0, 1, 3, 6, 24 Hours after dosing. Mean dose volume categories that were used to summarize data were as follows: 2 mL (range 0 to 3.5 mL) 5 mL (range 3.6 to 6 mL) 10 mL (range \>6 to 12 mL) 17 mL (range \>12 to 24 mL) 30 mL (range \>24 mL to 44 mL) 68 mL (range \>44 to 98 mL) 118 mL (range \>98 to 175 mL)
Time frame: T= 0, 1, 3, 6, 24 hours
Exploratory: Control or Regression of Non Injected Tumors by Measurement of Length (in Centimeters) Radio-graphically Using Computer Tomography or Magnetic Resonance Imaging.
Characterize response in non-injected lesions (up to 5) using length (cm) as the key parameter for measurement.
Time frame: Up to 18 months
Exploratory: Blood, Genetic and Tissue Biomarker Identification From Cell Flow Phenotyping, Tissue Analysis, Genetic SNP Analysis.
Evaluate various tumor and anti-tumor immune response biomarkers from blood, tumor tissue that may correlate with tumor response. Flow and tissue panels may include Live-Dead, CD3, CD4, CD8, FoxP3, Ki-67, ICOS, DAPI, PD-1, LAG-3, TIM-3, CTLA-4 and analysis of blood serum cytokine such as Th1/Th2, IFN-γ, IL-1β, IL-2, IL-4, IL-6, IL-8, IL-10, IL-12 p70, IL-13, and TNF-α.
Time frame: Up to 2 months
Exploratory: Overall Subject Outcome
Evaluate overall response by iRECIST including survival
Time frame: Up to 3 years
| Milestone | Monotherapy: Cohort A1 | Monotherapy: Cohort B1 | Monotherapy: Cohort EA | Monotherapy: Cohort EC | Monotherapy: Cohort EC-2 | Monotherapy: Cohort EC3 | INT 230-6 Combined With Pembrolizumab (Cohort DEC) | INT 230-6 Combined With Pembrolizumab (Cohort DEC2) | INT 230-6 Combined With Ipilimumab (Cohort FEC) |
|---|---|---|---|---|---|---|---|---|---|
| Started | 6 | 4 | 4 | 21 | 20 | 9 | 6 | 22 | 18 |
| Completed | 1 | 1 | 1 | 9 | 9 | 3 | 3 | 5 | 13 |
| Not completed | 5 | 3 | 3 | 12 | 11 | 6 | 3 | 17 | 5 |
| Withdrew: Radiographic deterioration | 0 | 3 | 1 | 2 | 6 | 3 | 0 | 4 | 2 |
| Withdrew: Adverse event | 2 | 0 | 1 | 3 | 1 | 0 | 1 | 3 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 2 | 0 | 2 | 0 | 4 | 1 |
| Withdrew: Physician decision | 1 | 0 | 0 | 2 | 1 | 0 | 2 | 3 | 0 |
| Withdrew: Clinical deterioration | 2 | 0 | 0 | 2 | 1 | 1 | 0 | 3 | 2 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Refused further treatment | 0 | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Rapid progression of disease | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
The primary objective is to assess the safety and tolerability of single and multiple intratumoral doses of INT230-6 in subjects with advanced or recurrent malignancies. This will be assessed by the rate of ≥ grade 3 AE's attributed to INT230-6 and not the underlying disease. NCI Common Terminology Criteria for Adverse Events (CTCAE v.4.03) (Scale 1 (least severe) to 5 (most severe)) All recorded adverse events will be listed and tabulated by system organ class, preferred term, and dose and coded according to the most current version of MedDRA. The incidence of adverse events will be tabulated and reviewed for potential significance and clinical importance. Adverse Events will be summarized for all reported data and by study period: a) up to and including 28 days post last dose of initial treatment, and b) from first dose of re-initiation of treatment, for subjects who re-initiate study therapy while in follow-up, up to 28 days post-dose of the last re-treatment dose.
| Participants | Monotherapy: Cohort A1 | Monotherapy: Cohort B1 | Monotherapy: Cohort EA | Monotherapy: Cohort EC | Monotherapy: Cohort EC-2 | Monotherapy: Cohort EC3 | INT 230-6 Combined With Pembrolizumab (Cohort DEC) | INT 230-6 Combined With Pembrolizumab (Cohort DEC2) | INT 230-6 Combined With Ipilimumab (Cohort FEC) |
|---|---|---|---|---|---|---|---|---|---|
| Rate and Severity of Treatment-emergent Adverse Events ≥ Grade 3 Attributed to Study Drug Using the NCI Common Terminology Criteria for Adverse Events (CTCAE v.4.03) (Scale 1 to 5) | 0 | 0 | 1 | 2 | 4 | 0 | 1 | 6 | 2 |
Assess the preliminary efficacy of INT230-6 by measuring the disease control rate (CR+PR+SD) as assessed by iRECIST. Complete response (CR) and partial response (PR) will be defined for injected tumors followed per RECIST 1.1 utilizing target lesions. Progressive disease will be determined by clinical or radiological deterioration leading to the subject being taken off-treatment at the discretion of the investigator. Stable disease (SD) is defined as any adequate assessment not considered CR, PR, or progression.
| percentage (DCR) | Monotherapy (Cohorts A1/B1/EA/EC/EC2/EC3) [Dosed >/= 40%TTB] | Monotherapy (Cohorts A1/B1/EA/EC/EC2/EC3) [Dosed <40%TTB] | INT230-6 Combined With Pembrolizumab (Cohorts DEC/DEC2) | INT 230-6 Combined With Ipilimumab (Cohort FEC) |
|---|---|---|---|---|
| Preliminary Efficacy: Assess the Preliminary Efficacy of INT230-6 by Measuring the Disease Control Rate (DCR) Based on the Response Evaluation Criteria in Solid Tumors (RECIST) and Immune RECIST (iRECIST) Criteria, | 83.3 | 50.0 | 64.3 | 83.3 |
Characterize the peak plasma profile for the three INT230-6 components after single and then multiple IT tumor site injections for safety purposes. Timepoints for sample collection were T = 1 Hours after dosing. Mean dose volume categories that were used to summarize data were as follows: 2 mL (range 0 to 3.5 mL) 5 mL (range 3.6 to 6 mL) 10 mL (range \>6 to 12 mL) 17 mL (range \>12 to 24 mL) 30 mL (range \>24 mL to 44 mL) 68 mL (range \>44 to 98 mL) 118 mL (range \>98 to 175 mL)
| ng/mL | Pharmacokinetic (PK) Analysis Population (Component 1: Cisplatin) | Pharmacokinetic Analysis Population (Component 2: SHAO) | Pharmacokinetic Analysis Population (Component 3: Vinblastine) |
|---|---|---|---|
| Mean INT230-6 Dose Category: 2mL | 34.27 ± 25.51 | 74.93 ± 70.8 | 1.35 ± 1.7 |
| Mean INT230-6 Dose Category: 5mL | 77.81 ± 38.16 | 113.7 ± 83.2 | .73 ± .77 |
| Mean INT230-6 Dose Category: 10mL | 153.8 ± 65.75 | 300.6 ± 172.6 | .75 ± .33 |
| Mean INT230-6 Dose Category: 17mL | 245.8 ± 119.3 | 426.8 ± 306.6 | 1.24 ± .67 |
| Mean INT230-6 Dose Category: 30mL | 456.5 ± 195.0 | 911.6 ± 790.1 | 3.16 ± 1.99 |
| Mean INT230-6 Dose Category: 68mL | 952.2 ± 503.8 | 1446 ± 1245 | 5.63 ± 2.33 |
| Mean INT230-6 Dose Category: 118mL | 1673 ± 1276 | 2720 ± 1848 | 9.52 ± 4.52 |
Characterize the pharmacokinetic AUC profile of each of the three INT230-6 components for AUC after single IT tumor site injection for safety purposes. Timepoints for sample collection were T = 0, 1, 3, 6, 24 Hours after dosing. Mean dose volume categories that were used to summarize data were as follows: 2 mL (range 0 to 3.5 mL) 5 mL (range 3.6 to 6 mL) 10 mL (range \>6 to 12 mL) 17 mL (range \>12 to 24 mL) 30 mL (range \>24 mL to 44 mL) 68 mL (range \>44 to 98 mL) 118 mL (range \>98 to 175 mL)
| ng/mL | Pharmacokinetic (PK) Analysis Population (Component 1: Cisplatin) | Pharmacokinetic Analysis Population (Component 2: SHAO) | Pharmacokinetic Analysis Population (Component 3: Vinblastine) |
|---|---|---|---|
| Mean INT230-6 Dose Category: 2mL Time point: 0 Hours | 6.38 ± 20.18 | 0 ± 0 | .33 ± 1.05 |
| Mean INT230-6 Dose Category: 2mL Time point: 1 Hour(s) | 33.78 ± 24.92 | 59.94 ± 69.95 | .08 ± .16 |
| Mean INT230-6 Dose Category: 2mL Timepoint: 3 Hours | 28.09 ± 23.16 | 3.33 ± 6.99 | .04 ± .12 |
| Mean INT230-6 Dose Category: 2mL Timepoint: 6 Hours | 25.35 ± 20.35 | 0 ± 0 | 0 ± 0 |
| Mean INT230-6 Dose Category: 2mL Timepoint: 24 Hours | 20.74 ± 17.22 | 0 ± 0 | 0 ± 0 |
| Mean INT230-6 Dose Category: 5mL Timepoint: 0 Hours | 1.56 ± 4.67 | 0 ± 0 | 0 ± 0 |
| Mean INT230-6 Dose Category: 5mL Timepoint: 1 Hour(s) | 77.81 ± 38.16 | 113.74 ± 83.23 | .65 ± .76 |
| Mean INT230-6 Dose Category: 5mL Timepoint: 3 Hours | 58.50 ± 30.57 | 11.43 ± 15.52 | .16 ± .16 |
| Mean INT230-6 Dose Category: 5mL Timepoint: 6 Hours | 59.04 ± 32.03 | 2.18 ± 6.15 | 0 ± 0 |
| Mean INT230-6 Dose Category: 5mL Timepoint: 24 Hours | 53.87 ± 29.07 | 0 ± 0 | 0 ± 0 |
| Mean INT230-6 Dose Category: 10mL Timepoint: 0 Hours | 4.95 ± 13.09 | 0 ± 0 | 0 ± 0 |
| Mean INT230-6 Dose Category: 10mL Timepoint: 1 Hour(s) | 152.63 ± 67.36 | 300.56 ± 172.62 | .74 ± .35 |
| Mean INT230-6 Dose Category: 10mL Timepoint: 3 Hours | 114.7 ± 53.38 | 36.68 ± 51.13 | .39 ± .22 |
| Mean INT230-6 Dose Category: 10mL Timepoint: 6 Hours | 111.57 ± 49.37 | 6.21 ± 15.22 | .34 ± .1 |
| Mean INT230-6 Dose Category: 10mL Timepoint: 24 Hours | 100.98 ± 52.36 | 0 ± 0 | .05 ± .12 |
| Mean INT230-6 Dose Category: 17mL Timepoint: 0 Hours | 4.99 ± 19.50 | 0 ± 0 | .01 ± .06 |
| Mean INT230-6 Dose Category: 17mL Timepoint: 1 Hours | 233.15 ± 125.77 | 426.75 ± 306.59 | 1.2 ± .72 |
| Mean INT230-6 Dose Category: 17mL Timepoint: 3 Hours | 187.08 ± 93.22 | 59.76 ± 45.33 | .66 ± .35 |
| Mean INT230-6 Dose Category: 17mL Timepoint: 6 Hours | 176.45 ± 90.26 | 19.49 ± 19.77 | .51 ± .29 |
| Mean INT230-6 Dose Category: 17mL Timepoint:24 Hours | 163.87 ± 90.19 | .5 ± 2.27 | .17 ± .24 |
| Mean INT230-6 Dose Category: 30mL Timepoint: 0 Hours | 7.15 ± 19.24 | 0.0 ± 0 | 0 ± 0 |
| Mean INT230-6 Dose Category: 30mL Timepoint: 1 Hours | 456.47 ± 195.02 | 911.55 ± 790.14 | 3.16 ± 1.99 |
| Mean INT230-6 Dose Category: 30mL Timepoint: 3 Hours | 344.82 ± 163.12 | 95.67 ± 64.38 | 1.44 ± .77 |
| Mean INT230-6 Dose Category: 30mL Timepoint: 6 Hours | 325.73 ± 152.91 | 26.95 ± 20.34 | 1.06 ± .58 |
| Mean INT230-6 Dose Category: 30mL Timepoint: 24 Hours | 295.42 ± 137.46 | .78 ± 3.20 | .47 ± .38 |
| Mean INT230-6 Dose Category: 68mL Timepoint: 0 Hours | 62.93 ± 222.70 | 289.23 ± 1042.84 | .44 ± 1.58 |
| Mean INT230-6 Dose Category: 68mL Timepoint: 1 Hours | 832.92 ± 192.93 | 1286.00 ± 1039.43 | 5.53 ± 2.35 |
| Mean INT230-6 Dose Category: 68mL Timepoint: 3 Hours | 741.92 ± 343.37 | 240.82 ± 276.13 | 2.73 ± .72 |
| Mean INT230-6 Dose Category: 68mL Timepoint: 6 Hours | 775.00 ± 581.44 | 96.54 ± 146.88 | 1.94 ± .55 |
| Mean INT230-6 Dose Category: 68mL Timepoint: 24 Hours | 610.08 ± 264.39 | 2.71 ± 6.44 | .94 ± .43 |
| Mean INT230-6 Dose Category: 118mL Timepoint: 0 Hours | 0 ± 0 | 0 ± 0 | .08 ± .17 |
| Mean INT230-6 Dose Category: 118mL Timepoint: 1 Hours | 1664 ± 1287.53 | 2719.75 ± 1848.17 | 9.52 ± 4.52 |
| Mean INT230-6 Dose Category: 118mL Timepoint: 3 Hours | 875 ± 433.39 | 459.67 ± 289.46 | 4.33 ± 1.46 |
| Mean INT230-6 Dose Category: 118mL Timepoint: 6 Hours | 779.67 ± 360.88 | 183.43 ± 99.64 | 3.08 ± .85 |
| Mean INT230-6 Dose Category: 118mL Timepoint: 24 Hours | 945.33 ± 544.78 | 21.93 ± 24.84 | 1.24 ± 1.19 |
Characterize the half life of each of the three INT230-6 components after single and multiple IT tumor site injections for safety purposes. Timepoints for sample collection were T = 0, 1, 3, 6, 24 Hours after dosing. Mean dose volume categories that were used to summarize data were as follows: 2 mL (range 0 to 3.5 mL) 5 mL (range 3.6 to 6 mL) 10 mL (range \>6 to 12 mL) 17 mL (range \>12 to 24 mL) 30 mL (range \>24 mL to 44 mL) 68 mL (range \>44 to 98 mL) 118 mL (range \>98 to 175 mL)
| Hours | Pharmacokinetic (PK) Analysis Population (Component 1: Cisplatin) | Pharmacokinetic Analysis Population (Component 2: SHAO) | Pharmacokinetic Analysis Population (Component 3: Vinblastine) |
|---|---|---|---|
| Mean INT230-6 Dose Category: 2mL | 77.98 ± 34.92 | — | — |
| Mean INT230-6 Dose Category: 5mL | 130.4 ± 129.8 | — | — |
| Mean INT230-6 Dose Category: 10mL | 106.3 ± 53.58 | — | 18.82 |
| Mean INT230-6 Dose Category: 17mL | 78.73 ± 66.36 | 7.33 | 20.11 ± 7.45 |
| Mean INT230-6 Dose Category: 30mL | 64.77 ± 15.18 | 7.48 | 15.35 ± 4.38 |
| Mean INT230-6 Dose Category: 68mL | 129.4 ± 125.5 | 3.91 ± 2.6 | 14.06 ± 3.7 |
| Mean INT230-6 Dose Category: 118mL | — | 6.18 | 24.48 ± 4.76 |
Characterize response in non-injected lesions (up to 5) using length (cm) as the key parameter for measurement.
Results for this outcome have not been posted.
Evaluate various tumor and anti-tumor immune response biomarkers from blood, tumor tissue that may correlate with tumor response. Flow and tissue panels may include Live-Dead, CD3, CD4, CD8, FoxP3, Ki-67, ICOS, DAPI, PD-1, LAG-3, TIM-3, CTLA-4 and analysis of blood serum cytokine such as Th1/Th2, IFN-γ, IL-1β, IL-2, IL-4, IL-6, IL-8, IL-10, IL-12 p70, IL-13, and TNF-α.
Results for this outcome have not been posted.
Evaluate overall response by iRECIST including survival
Results for this outcome have not been posted.
Collected over Each patient would have their Adverse Events recorded starting at the first dose until 28 days after the last dose. up to 5 years.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Monotherapy: (Cohort A1) | 0/6 (0%) | 0/6 (0%) | 4/6 (66.7%) |
| Monotherapy: (Cohort B1) | 0/4 (0%) | 0/4 (0%) | 2/4 (50%) |
| Monotherapy: (Cohort E-A) | 0/4 (0%) | 0/4 (0%) | 3/4 (75%) |
| Monotherapy: (Cohort E-C) | 0/21 (0%) | 1/21 (4.8%) | 20/21 (95.2%) |
| Monotherapy: (Cohort EC-2) | 0/20 (0%) | 1/20 (5%) | 20/20 (100%) |
| Monotherapy: (Cohort EC3) | 0/9 (0%) | 1/9 (11.1%) | 7/9 (77.8%) |
| INT230-6 Combined With Pembrolizumab (Cohorts DEC) | 0/8 (0%) | 2/8 (25%) | 7/8 (87.5%) |
| INT230-6 Combined With Pembrolizumab (Cohorts DEC2) | 0/22 (0%) | 2/22 (9.1%) | 19/22 (86.4%) |
| INT 230-6 Combined With Ipilimumab (Cohort FEC) | 0/18 (0%) | 1/18 (5.6%) | 16/18 (88.9%) |
| Event | Monotherapy: (Cohort A1) | Monotherapy: (Cohort B1) | Monotherapy: (Cohort E-A) | Monotherapy: (Cohort E-C) | Monotherapy: (Cohort EC-2) | Monotherapy: (Cohort EC3) | INT230-6 Combined With Pembrolizumab (Cohorts DEC) | INT230-6 Combined With Pembrolizumab (Cohorts DEC2) | INT 230-6 Combined With Ipilimumab (Cohort FEC) |
|---|---|---|---|---|---|---|---|---|---|
| VomitingGastrointestinal disorders | 0/6 | 0/4 | 0/4 | 0/21 | 0/20 | 0/9 | 1/8 | 0/22 | 0/18 |
| HeadacheNervous system disorders | 0/6 | 0/4 | 0/4 | 0/21 | 0/20 | 0/9 | 1/8 | 0/22 | 0/18 |
| Localized Tumor Related PainGeneral disorders | 0/6 | 0/4 | 0/4 | 0/21 | 1/20 | 1/9 | 0/8 | 0/22 | 0/18 |
| ColitisGastrointestinal disorders | 0/6 | 0/4 | 0/4 | 0/21 | 0/20 | 0/9 | 0/8 | 0/22 | 1/18 |
| Procedural PainInjury, poisoning and procedural complications | 0/6 | 0/4 | 0/4 | 1/21 | 0/20 | 0/9 | 0/8 | 0/22 | 0/18 |
| SepsisInfections and infestations | 0/6 | 0/4 | 0/4 | 0/21 | 0/20 | 0/9 | 0/8 | 1/22 | 0/18 |
| PneumothoraxRespiratory, thoracic and mediastinal disorders | 0/6 | 0/4 | 0/4 | 0/21 | 0/20 | 0/9 | 0/8 | 1/22 | 0/18 |
| Event | Monotherapy: (Cohort A1) | Monotherapy: (Cohort B1) | Monotherapy: (Cohort E-A) | Monotherapy: (Cohort E-C) | Monotherapy: (Cohort EC-2) | Monotherapy: (Cohort EC3) | INT230-6 Combined With Pembrolizumab (Cohorts DEC) | INT230-6 Combined With Pembrolizumab (Cohorts DEC2) | INT 230-6 Combined With Ipilimumab (Cohort FEC) |
|---|---|---|---|---|---|---|---|---|---|
| Localized Tumor-Related PainGeneral disorders | 2/6 | 2/4 | 3/4 | 13/21 | 14/20 | 6/9 | 5/8 | 10/22 | 9/18 |
| NauseaGastrointestinal disorders | 0/6 | 0/4 | 0/4 | 11/21 | 10/20 | 5/9 | 2/8 | 2/22 | 4/18 |
| FatigueGeneral disorders | 1/6 | 0/4 | 0/4 | 11/21 | 8/20 | 0/9 | 0/8 | 6/22 | 6/18 |
| VomitingGastrointestinal disorders | 0/6 | 0/4 | 0/4 | 10/21 | 6/20 | 1/9 | 3/8 | 3/22 | 3/18 |
| Decreased AppetiteMetabolism and nutrition disorders | 0/6 | 0/4 | 0/4 | 7/21 | 7/20 | 1/9 | 1/8 | 3/22 | 2/18 |
| AnaemiaBlood and lymphatic system disorders | 0/6 | 0/4 | 0/4 | 2/21 | 6/20 | 0/9 | 0/8 | 2/22 | 2/18 |
| Injection Site ErythemaGeneral disorders | 0/6 | 1/4 | 0/4 | 1/21 | 0/20 | 0/9 | 0/8 | 0/22 | 0/18 |
| PyrexiaGeneral disorders | 0/6 | 0/4 | 1/4 | 0/21 | 1/20 | 1/9 | 0/8 | 0/22 | 2/18 |
| HeadacheNervous system disorders | 0/6 | 0/4 | 1/4 | 1/21 | 0/20 | 0/9 | 1/8 | 0/22 | 2/18 |
| UrticariaSkin and subcutaneous tissue disorders | 0/6 | 0/4 | 1/4 | 1/21 | 0/20 | 0/9 | 0/8 | 0/22 | 0/18 |
| Age, Categorical(Participants) | Monotherapy: (Cohort A1) | Monotherapy: (Cohort B1) | Monotherapy: (Cohort E-A) | Monotherapy: (Cohort E-C) | Monotherapy: (Cohort EC-2) | Monotherapy: (Cohort EC3) | INT 230-6 Combined With Pembrolizumab (Cohort DEC) | INT 230-6 Combined With Pembrolizumab (Cohort DEC2) | INT 230-6 Combined With Ipilimumab (Cohort FEC) | Total |
|---|---|---|---|---|---|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 5 | 2 | 4 | 14 | 9 | 5 | 4 | 8 | 12 | 63 |
| >=65 years | 1 | 2 | 0 | 7 | 11 | 4 | 2 | 14 | 6 | 47 |
| Age, Continuous(years) | Monotherapy: (Cohort A1) | Monotherapy: (Cohort B1) | Monotherapy: (Cohort E-A) | Monotherapy: (Cohort E-C) | Monotherapy: (Cohort EC-2) | Monotherapy: (Cohort EC3) | INT 230-6 Combined With Pembrolizumab (Cohort DEC) | INT 230-6 Combined With Pembrolizumab (Cohort DEC2) | INT 230-6 Combined With Ipilimumab (Cohort FEC) | Total |
|---|---|---|---|---|---|---|---|---|---|---|
| Mean | 54.5 ± 7.1 | 61.5 ± 7.9 | 57.6 ± 4.1 | 59.0 ± 9.9 | 64.6 ± 9.4 | 61.5 ± 11.3 | 64.2 ± 16 | 68.4 ± 7.3 | 64.2 ± 11.1 | 62.9 ± 9.8 |
| Sex: Female, Male(Participants) | Monotherapy: (Cohort A1) | Monotherapy: (Cohort B1) | Monotherapy: (Cohort E-A) | Monotherapy: (Cohort E-C) | Monotherapy: (Cohort EC-2) | Monotherapy: (Cohort EC3) | INT 230-6 Combined With Pembrolizumab (Cohort DEC) | INT 230-6 Combined With Pembrolizumab (Cohort DEC2) | INT 230-6 Combined With Ipilimumab (Cohort FEC) | Total |
|---|---|---|---|---|---|---|---|---|---|---|
| Female | 4 | 3 | 2 | 11 | 7 | 6 | 3 | 8 | 10 | 54 |
| Male | 2 | 1 | 2 | 10 | 13 | 3 | 3 | 14 | 8 | 56 |
| Ethnicity (NIH/OMB)(Participants) | Monotherapy: (Cohort A1) | Monotherapy: (Cohort B1) | Monotherapy: (Cohort E-A) | Monotherapy: (Cohort E-C) | Monotherapy: (Cohort EC-2) | Monotherapy: (Cohort EC3) | INT 230-6 Combined With Pembrolizumab (Cohort DEC) | INT 230-6 Combined With Pembrolizumab (Cohort DEC2) | INT 230-6 Combined With Ipilimumab (Cohort FEC) | Total |
|---|---|---|---|---|---|---|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 1 | 2 | 2 | 2 | 0 | 3 | 3 | 13 |
| Not Hispanic or Latino | 6 | 4 | 3 | 19 | 18 | 7 | 6 | 19 | 15 | 97 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Monotherapy: (Cohort A1) | Monotherapy: (Cohort B1) | Monotherapy: (Cohort E-A) | Monotherapy: (Cohort E-C) | Monotherapy: (Cohort EC-2) | Monotherapy: (Cohort EC3) | INT 230-6 Combined With Pembrolizumab (Cohort DEC) | INT 230-6 Combined With Pembrolizumab (Cohort DEC2) | INT 230-6 Combined With Ipilimumab (Cohort FEC) | Total |
|---|---|---|---|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Asian | 0 | 1 | 0 | 3 | 2 | 2 | 1 | 5 | 1 | 15 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 1 | 0 | 0 | 2 | 0 | 0 | 0 | 2 | 2 | 7 |
| White | 5 | 3 | 4 | 16 | 18 | 5 | 5 | 13 | 13 | 82 |
| More than one race | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 2 | 2 | 6 |
| Region of Enrollment(participants) | Monotherapy: (Cohort A1) | Monotherapy: (Cohort B1) | Monotherapy: (Cohort E-A) | Monotherapy: (Cohort E-C) | Monotherapy: (Cohort EC-2) | Monotherapy: (Cohort EC3) | INT 230-6 Combined With Pembrolizumab (Cohort DEC) | INT 230-6 Combined With Pembrolizumab (Cohort DEC2) | INT 230-6 Combined With Ipilimumab (Cohort FEC) | Total |
|---|---|---|---|---|---|---|---|---|---|---|
| Canada | 3 | 0 | 0 | 1 | 1 | 0 | 4 | 1 | 1 | 11 |
| United States | 3 | 4 | 4 | 20 | 19 | 9 | 2 | 21 | 17 | 99 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Feb 2017 to primary completion in Feb 2023, 72 months.
Results were first posted in Aug 2024, 1 year 5 months after primary completion.
Of 164 industry-sponsored phase 1/2 interventional studies under Breast Neoplasms, half reached primary completion within 59 months of starting (the median), counting those still running; a quarter within 44 and three quarters within 75. This study's 72 months is above that.
Counting every sponsor, half of 331 studies reached it within 62 months; a quarter within 45 and three quarters within 88.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Cisplatin/Vinblastine/Cell Penetration Enhancer Formulation INT230-6
Intensity Therapeutics, Inc.